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Background: The inverse association between educational attainment and mortality is well established, but
its relevance to vascular events and renal progression in a population with chronic kidney disease (CKD) is
less clear. This study aims to determine the association between highest educational attainment and risk of
vascular events, cause-specific mortality, and CKD progression.
Study Design: Prospective epidemiologic analysis among participants in the Study of Heart and Renal
Protection (SHARP), a randomized controlled trial.
Setting & Participants: 9,270 adults with moderate to severe CKD (6,245 not receiving dialysis at baseline)
and no history of myocardial infarction or coronary revascularization recruited in Europe, North America, Asia,
Australia, and New Zealand.
Predictor: Highest educational attainment measured at study entry using 6 levels that ranged from “no
formal education” to “tertiary education.”
Outcomes: Any vascular event (any fatal or nonfatal cardiac, cerebrovascular, or peripheral vascular
event), cause-specific mortality, and CKD progression during 4.9 years’ median follow-up.
Results: There was a significant trend (P , 0.001) toward increased vascular risk with decreasing levels of
education. Participants with no formal education were at a 46% higher risk of vascular events (relative risk [RR],
1.46; 95% CI, 1.14-1.86) compared with participants with tertiary education. The trend for mortality across ed-
ucation levels was also significant (P , 0.001): all-causemortality was twice as high among those with no formal
education compared with tertiary-educated individuals (RR, 2.05; 95% CI, 1.62-2.58), and significant increases
were seen for both vascular (RR, 1.84; 95% CI, 1.21-2.81) and nonvascular (RR, 2.15; 95% CI, 1.60-2.89)
deaths. Lifestyle factors and prior disease explain most of the excess mortality risk. Among 6,245 participants
not receiving dialysis at baseline, education level was not significantly associated with progression to end-
stage renal disease or doubling of creatinine level (P for trend5 0.4).
Limitations: No data for employment or health insurance coverage.
Conclusions: Lower educational attainment is associated with increased risk of adverse health outcomes in
individuals with CKD.
Am J Kidney Dis. 67(1):31-39.ª 2016 The Authors. Published by Elsevier Inc. on behalf of the National Kidney
Foundation, Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/
by/4.0/).
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factor; socioeconomic factors; inequalities; renal dialysis; Study of Heart and Renal Protection (SHARP).
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Morton et allevels of smoking and better control of hypertension
associated with lower age-adjusted mortality, and
increased obesity associatedwith highermortality risk.6
However, studies of the relevance of educational
attainment to health outcomes in chronic kidney dis-
ease (CKD) are sparse.7 Two small studies of patients
on dialysis therapy have shown that poor health lit-
eracy (deﬁned as the ability to obtain, process, and
understand basic health information to make de-
cisions regarding one’s health and medical care) is
associated with 54% (hazard ratio [HR], 1.54; 95%
conﬁdence interval [CI], 1.01-2.35) higher risk of
death,8 and tertiary education compared with primary
school education only is associated with 46% (HR,
0.54; 95% CI, 0.32-0.91) lower cardiovascular
mortality.9
We used data from 9,270 participants with moderate
to severe CKD in the Study of Heart and Renal Pro-
tection (SHARP) to: (1) assess associations between
highest educational attainment (ie, level of schooling,
vocational, or tertiary education obtained early in life)
and particular health outcomes (vascular morbidity,
cause-speciﬁc mortality, and kidney disease progres-
sion) and (2) determine whether there are gradients in
health outcomes by educational attainment in moderate
to severe CKD. With more than 2,300 vascular events,
more than 2,200 deaths, and more than 2,400 partici-
pants doubling their creatinine levels or progressing to
end-stage renal disease (ESRD) during a median 4.9
years’ follow-up, the study provides an opportunity to
investigate associations between educational attain-
ment and health outcomes in a large and carefully
phenotyped population with CKD.
METHODS
Study Overview
SHARP was a randomized placebo-controlled trial investigating
the effects of lowering low-density lipoprotein cholesterol levels
for an average of 5 years with simvastatin, 20 mg, plus ezetimibe,
10 mg, daily on major vascular and kidney disease outcomes. The
study enrolled 9,270 participants with CKD (6,245 [67%] not
receiving and 3,025 [33%] receiving dialysis at baseline) in 18
countries.10 Study procedures and clinical results from the ran-
domized comparisons have been published previously.10,11 Pro-
cedures for the current analyses followed STROBE (Strengthening
the Reporting of Observational Studies in Epidemiology) guide-
lines12 and are summarized next.
Study Participants and Baseline Assessment
Individuals with CKD who were 40 years or older were eligible
to participate if they had more than one previous measurement of
serum or plasma creatinine of at least 1.7 mg/dL (150 mmol/L) in
men or 1.5 mg/dL (130 mmol/L) in women. Individuals with prior
myocardial infarction or coronary revascularization and those with
a medical history that might limit their ability to participate or take
study treatments for the duration of the study (eg, severe respira-
tory disease, history of cancer other than nonmelanoma skin
cancer, or recent history of alcohol or substance misuse) were
excluded. A 6-week run-in period was undertaken to identify and32exclude from randomization participants who were unlikely to
adhere to the study medication for the duration of the study. For
the purpose of the current analyses, baseline information refers
to information that was recorded at or shortly before a partici-
pant’s random assignment to simvastatin plus ezetimibe versus
placebo. Recorded baseline information included sociodemo-
graphic characteristics (such as age, sex, and ethnicity), blood
pressure, blood and urine test results, anthropometric measure-
ments to calculate body mass index (BMI), previous disease his-
tory, current medications, cigarette smoking, and alcohol
consumption. To facilitate the planned analysis of the impact of
educational attainment on health outcomes, the participant’s
highest educational level completed was recorded at trial entry
according to the relevant description in each country: postgraduate
tertiary education, undergraduate tertiary education, high school,
vocational studies, lower high school, primary school, or no
formal education (see separate country-speciﬁc classiﬁcations in
Table S1, available as online supplementary material). In addition,
participants without recorded education data were categorized as
“unrecorded.” Due to the small number of participants with
postgraduate tertiary education, the top 2 education categories
were combined to make one tertiary education level. Estimated
glomerular ﬁltration rate (eGFR) was calculated using the CKD-
EPI (CKD Epidemiology Collaboration) creatinine equation.13
Follow-up Procedures and Study Outcomes
Participants were to be seen in person at 2, 6, and 12 months and
every 6months thereafter for at least 4 years. At each visit, information
for all serious adverse events (including vascular events, revasculari-
zation procedures, and initiation of renal replacement therapy),
adherence to study medication, and use of concomitant medication
was collected; further information was also sought from hospital and
other health records. Trained clinicians at the international coordi-
nating center adjudicated major study outcomes, including cause-
speciﬁc mortality, using standardized deﬁnitions and procedures.
For current analyses, the main vascular outcome of interest is “any
vascular event” during the study, deﬁned as nonfatal myocardial
infarction, coronary death, hemorrhagic and nonhemorrhagic stroke,
arterial revascularization, noncoronary cardiac death; atherosclerotic
other coronary, other cerebrovascular, other peripheral arterial disease
events; and nonfatal nonischemic heart failure, arrhythmias, or
valvular heart disease (see Item S1). Mortality was subdivided into
vascular and nonvascular (ie, renal, cancer, respiratory, or other
nonvascular) causes. To further understand the possible relevance of
educational attainment to respiratory and cancer deaths, exploratory
analyses of cancer incidence and nonfatal respiratory events were
undertaken. Among participants not receiving dialysis at baseline, the
main kidney disease outcomes in this analysis included 2 composite
end points: (1) progression to ESRD (deﬁned as kidney trans-
plantationor initiation ofmaintenance dialysis therapy) or doublingof
creatinine level and (2) progression to ESRDor death. In addition, the
availability of serial creatinine measurements allowed for estimation
of each individual’s annual rate of change in eGFR over time.14
Statistical Analysis
The relevance of highest educational attainment to ﬁrst occurrence
of disease outcomes of interestwas estimated usingCox proportional
hazardsmodels stratiﬁed by country of recruitment. The proportional
hazard assumption was tested through examination of the time-
dependency of the Schoenfeld residuals.15 The gradient in health
outcomes across all education levels, before and after adjustment for
potential mediators (see text that follows), was estimated usingWald
c2 tests for trend after excludingparticipants forwhomeducationwas
unrecorded. The c2 statistics allow for a quantitative assessment of
both the extent to which the mediators explain any education gra-
dients and the residual (ie, unexplained) relevance of education to
risk after adjustment for the recorded mediators.Am J Kidney Dis. 2016;67(1):31-39
Impact of Education on Outcomes in CKDLinear regression models were used to assess the relevance of
education level to rate of decline in eGFR. All analyses were
adjusted for age, sex, ethnicity (black vs white/other), and allo-
cation to simvastatin plus ezetimibe (vs placebo) and stratiﬁed by
country of recruitment. The relationship between educational
attainment and health outcomes was compared in the 2 treatment
groups (simvastatin plus ezetimibe vs placebo) with a test for
heterogeneity. Models for estimating total effects of education on
health outcomes did not adjust for the following variables because
they were assumed to be on the causal pathway between educa-
tional attainment and the outcomes of interest: cigarette smoking,
current alcohol consumption, BMI, comorbid conditions (vascular
disease and diabetes mellitus), CKD stage, renal diagnosis, sys-
tolic blood pressure, diastolic blood pressure, albumin level, uri-
nary albumin-creatinine ratio, hemoglobin level, phosphate level,
high-density lipoprotein cholesterol level, and total cholesterol
level (Fig S1).16 Deﬁnitions for model covariates are provided in
Item S2. Cox proportional hazards models were compared before
and after inclusion of all available potential effect mediators to
examine how the relationships observed across education levels
depended on these variables and to assess the extent to which
the association was explained by them. Associations between
educational level and behavioral risk factors (smoking, obesity
[BMI . 30 kg/m2], alcohol use, and adherence to allocated study
treatment [simvastatin plus ezetimibe or placebo]) were assessed
using logistic regression models stratiﬁed by country or region of
recruitment.17
For descriptive statistics, P values for differences between edu-
cation levels (heterogeneity or trend) were calculated using likeli-
hood ratio test statistics from linear regression models for
continuous variables and logistic regression models for categorical
variables.18 In the graphical ﬁgures, relative risks (RRs: approxi-
mated by the HR estimates from the Coxmodels) for each education
group are presented as “ﬂoating absolute risks,” which assign an
appropriate variance to the log of the RR in each group, including
the reference group of tertiary education.19 All RRs quoted in the
text are, unless stated otherwise, for each educational level versus
tertiary education. STATA, version 13 (StataCorp LP), and SAS,
version 9 (SAS Institute Inc), software were used for statistical
modeling.
RESULTS
Characteristics of Study Participants by Education
Level
In SHARP, 9,270 participants from 18 countries
were randomly assigned to simvastatin plus ezetimibe
versus placebo (mean age 62 years; 63% men; 72%
white; 22% Asian; 3% black; and 3% other ethnicity).
Of them, 11% completed tertiary education; 14%, high
school; 23%, vocational qualiﬁcations; 19%, lower
high school; and 15%, primary school; 4% completed
no formal education, and datawere unrecorded for 14%
(Table 1). Those with lower educational attainment
were more likely to be older, women, from Asia,
receiving dialysis, and a current smoker.
Vascular Events
During a median of 4.9 years’ follow-up, 2,317
participants experienced at least one vascular event (66/
1,000 patients per year [ppy]). There was a signiﬁcant
trend toward increasing vascular event risk with
lower levels of educational attainment (c2 5 16.12;Am J Kidney Dis. 2016;67(1):31-39P , 0.001; Fig 1A). Compared with tertiary-educated
individuals, vascular event risk was 46% higher
among those with no formal education (RR, 1.46; 95%
CI, 1.14-1.86). After adjustment for potential effect
mediators, including cigarette smoking, alcohol use,
obesity, adherence to study medication, CKD stage,
and comorbid conditions, the effect of educational
attainment on vascular riskwas substantially attenuated
and the trend was no longer statistically signiﬁcant
(c2 5 0.81; P 5 0.4; Fig 1B).
Mortality
There were 2,257 participants who died during
follow-up, including 749 from a deﬁnitely vascular
cause (19/1,000 ppy), 1,280 from a deﬁnitely
nonvascular cause (32/1,000 ppy), and 228 (6/1,000
ppy) from an unknown cause. Across levels of edu-
cation, there was a signiﬁcant trend toward increased
risk of vascular death (c2 5 14.23; P , 0.001),
nonvascular death (c2 5 29.42; P , 0.001), and all-
cause death (c2 5 51.52; P , 0.001; Fig 2A) with
lower educational attainment. All-cause mortality was
twice as high among those with no formal education
compared with tertiary-educated participants (RR,
2.05; 95% CI, 1.62-2.58), with signiﬁcant increases
seen for both vascular (RR, 1.84; 95% CI, 1.21-2.81)
and nonvascular (RR, 2.15; 95% CI, 1.60-2.89) cau-
ses of death (Fig 2A). After adjustment for potential
effect mediators, trend c2 test results decreased by
more than half (vascular death: c2 5 2.76; P 5 0.1;
nonvascular death: c2 5 9.18; P 5 0.002; and all-
cause death: c2 5 15.09; P , 0.001, respectively;
Fig 2B).
Of the 1,280 nonvascular deaths during the study,
337 (26%) were due to kidney failure; 278 (22%) to
cancer; 224 (18%) to respiratory causes; and 441
(34%) to other causes. Deaths due to kidney failure,
cancer, and respiratory causes were inversely associ-
ated with highest educational attainment (test for
trend across education levels: c2 5 10.24; P 5 0.001;
c2 5 6.08; P 5 0.01; and c2 5 9.24; P 5 0.002,
respectively; Fig S2). There was no trend for the
outcome of incident cancer or death from cancer
across education levels (trend c2 5 0.94; P 5 0.3),
but there was a trend across education levels for
respiratory event or death from respiratory disease
(trend c2 5 30.73; P , 0.001; Fig S3).
Progression of CKD
Among 6,245 participants not receiving dialysis at
baseline, 2,446 progressed to ESRD or their creati-
nine level doubled during follow-up (118/1,000 ppy).
However, there was no signiﬁcant association be-
tween highest educational attainment and this com-
posite kidney disease outcome (trend c2 5 0.71;
P 5 0.4; Fig 3). Similarly, there was no association33
Table 1. Characteristics of the 9,270 SHARP Participants by Highest Education Level Attained at Study Entry
Characteristic at
Study Entry
Tertiary
Education
(n 5 1,062)
High
School
(n 5 1,271)
Vocational
Qualifications
(n 5 2,127)
Lower
High
School
(n 5 1,754)
Primary
School
(n 5 1,378)
No Formal
Education
(n 5 347)
Education
Unrecorded
(n 5 1,331)
P Valuesa for
Heterogeneity
or Trendb
Across
Education
Levels
Age, y 616 12 59 6 12 61 6 12 60 6 12 63 6 12 67 6 11 62 6 12 ,0.001
Sex ,0.001
Male 73 67 67 55 57 44 63
Female 27 33 33 45 43 56 37
Ethnicity ,0.001
White 75 60 88 70 54 43 83
Black 4 8 1 2 1 3 2
Asian 19 29 9 26 40 51 10
Other 2 3 2 2 5 4 5
Region ,0.001
Europe 54 42 78 56 34 42 61
North America 16 19 5 8 8 3 9
Australia/NZ 16 12 8 14 19 6 22
China 9 14 7 14 13 22 ,1
Southeast Asia 5 13 2 8 26 27 8
Smokingc
Never 63 53 51 48 45 47 53 0.002b
Former 32 35 37 37 36 31 34 0.06b
Current 6 11 12 15 20 23 12 ,0.001b
Current alcohol usec 36 28 29 25 18 14 27 ,0.001b
BMI, kg/m2,c 26.5 6 5.5 26.9 6 5.6 27.4 6 5.8 27.5 6 5.5 27.2 6 5.7 26.9 6 5.6 26.8 6 5.7 ,0.001b
History of diabetes mellitusc 19 21 24 23 25 22 21 ,0.001b
History of vascular diseasec 11 14 16 16 18 17 14 0.008b
Albumin, g/dLc 4.03 6 0.34 4.03 6 0.42 4.01 6 0.34 3.99 6 0.40 3.99 6 0.37 3.97 6 0.42 4.01 6 0.35 0.002b
Hemoglobin, g/dLc 12.1 6 2.1 12.2 6 2.1 12.1 6 2.3 11.9 6 2.1 11.9 6 2.2 11.9 6 2.0 12.1 6 2.2 ,0.001b
Renal diagnosisc
Diabetic nephropathy 12 14 15 15 17 12 13
Cystic kidney disease 16 12 11 10 8 10 11
Otherd 71 74 74 74 74 77 76
ln(UACR), mg/gc 5.06 1.8 5.2 6 1.8 5.3 6 1.9 5.3 6 1.8 5.4 6 1.9 5.4 6 1.8 5.3 6 1.8 0.001b
Systolic BP, mm Hgc 137 6 22 138 6 22 140 6 23 139 6 22 142 6 22 141 6 22 138 6 23 ,0.001b
Diastolic BP, mm Hgc 796 13 79 6 13 79 6 13 79 6 12 79 6 13 80 6 13 78 6 13 0.4b
Total cholesterol, mmol/Lc 4.91 6 1.1 4.92 6 1.2 4.89 6 1.2 4.90 6 1.1 4.81 6 1.2 4.71 6 1.2 4.90 6 1.2 0.03b
LDL cholesterol, mmol/Lc 2.79 6 0.9 2.80 6 0.9 2.77 6 0.9 2.81 6 0.9 2.73 6 0.9 2.67 6 0.9 2.76 6 0.9 0.03b
eGFR, mL/min/1.73 m2,c,e 26.0 6 12.7 25.6 6 12.8 25.0 6 12.8 25.0 6 12.8 24.8 6 13.0 24.2 6 12.8 24.7 6 12.7 0.07b
CKD stagec
3f 25 23 23 22 19 17 20 ,0.001
4 32 31 32 29 27 30 28
5, not on RRT 15 16 15 16 16 16 15
RRT 27 30 29 33 39 38 36
Note: Values for categorical variables are given as percentage; for continuous variables, as mean 6 standard deviation. There were
no significant differences in allocation to study medication (simvastatin plus ezetimibe vs placebo) across education levels, Pearson
c2 5 2.28; P 5 0.9. The subgroups of highest educational attainment are mutually exclusive.
Abbreviations and definitions: BMI, body mass index; BP, blood pressure; CKD, chronic kidney disease stage calculated using the
CKD-EPI (CKD Epidemiology Collaboration) creatinine equation13; eGFR, estimated glomerular filtration rate; NZ, New Zealand; RRT,
renal replacement therapy; SHARP, Study of Heart and Renal Protection; UACR, urinary albumin-creatinine ratio.
aP values are calculated using likelihood ratio test statistics from linear regression models for continuous baseline variables and
logistic regression models for categorical baseline variables, with further adjustment for age, sex, ethnicity, and country.18
bIn tests for trend, the highest education category is coded as 1, next highest as 2, and so on; education unrecorded category is
excluded. The difference in minus twice the log likelihood statistic between nested models that include and exclude this education term
was used to obtain a trend P value.
cAdjusted for age, sex, black ethnicity, study treatment allocation, and country.
dOther renal diagnosis includes glomerulonephritis, n5 1,723; hypertensive disease, n5 1,397; pyelonephritis, n 5 607; and other
known and unknown disease, n 5 2,823.
eFor patients not on dialysis therapy.
fPredominantly CKD stage 3b patients.
34 Am J Kidney Dis. 2016;67(1):31-39
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Figure 1. Relevance of highest education level attained to 2,317 vascular events (atherosclerotic and nonatherosclerotic). (A) Total
effect: Cox proportional hazards model stratified by country and adjusted for age, sex, black ethnicity, and study treatment assignment.
Test for trend c2 5 16.12; P, 0.001. (B) Residual effect: Cox proportional hazards model stratified by country and adjusted for age,
sex, black ethnicity, smoking, alcohol use, body mass index, chronic kidney disease stage, prior vascular disease, diabetes, renal diag-
nosis, systolic and diastolic blood pressure, albumin level, urinary albumin-creatinine ratio, hemoglobin level, phosphate level, high-
density lipoprotein cholesterol level, and total cholesterol level. The size of the square representing a relative risk is proportional to
its inverse variance; error bars represent 95% confidence intervals (CIs). Tests for trend in the models were evaluated after excluding
participants with unrecorded education. Test for trend c2 5 0.81; P 5 0.4.
Impact of Education on Outcomes in CKDbetween highest educational attainment and CKD
progression at any CKD stage (Fig S4).
Among participants not receiving dialysis at
baseline, the mean annual rate of decline in eGFR
was 2.19 mL/min/1.73 m2. A strong inverse asso-
ciation between baseline eGFR and rate of decline
was observed (ie, participants with a higher eGFR
progressed more slowly; Fig S5). However, the rate
of decline did not differ signiﬁcantly across
education levels overall or in any subgroup of
CKD stage (all P values for trend not statistically
signiﬁcant).
Among the 6,245 participants not receiving dialysis
at baseline, 2,994 participants progressed to ESRD or
died during follow-up. There was a signiﬁcant trend
toward increased risk of ESRD or death across levels
of educational attainment (c2 5 11.27; P , 0.001;
Fig S6A). Participants with no formal education
had 32% higher risk of ESRD or death compared
with tertiary-educated participants (RR, 1.32; 95% CI,
1.08-1.62). Following adjustment for potential effect
mediators, the trend attenuated and was no longer
statistically signiﬁcant (c2 5 2.59; P 5 0.1; Fig S6B).
Associations between education level and health
outcomes did not differ by randomized treatment
assignment (ie, there were nonsigniﬁcant tests for
interactions), except for progression to ESRD or
doubling of creatinine level (P 5 0.02).Am J Kidney Dis. 2016;67(1):31-39Health Behaviors
There was a higher likelihood of being a current
smoker at baseline among people with lower edu-
cational attainment (test for trend c2 5 98.09;
P , 0.001). Furthermore, of 4,515 participants who
had ever smoked, participants with higher educational
attainment were more likely to have quit smoking than
those with lower educational attainment (c2 5 48.00;
P , 0.001; Table S2). Lower educational attainment
was associated with higher probability of obesity
(ie, BMI$ 30 kg/m2 [c25 5.13; P5 0.02]), but was
associated with lower baseline alcohol use (c25 29.46;
P, 0.001). Among 8,757 participants with data for
adherence to study medication at 12 months, there
was no statistically signiﬁcant trend across levels of
educational attainment (c25 0.90; P5 0.3).
DISCUSSION
In this study,which to our knowledge is theﬁrst large
study of the relevance of educational attainment in
moderate to severe CKD, we observed consistent and
signiﬁcant gradients in vascular risk and mortality
across 6 education levels. These gradients were sub-
stantially attenuated following adjustment for available
effect mediators (ie, lifestyle factors, comorbid con-
ditions, and CKD stage). Educational level was not
associated with progression of CKD in this population.35
Figure 2. Relevance of highest education level attained to vascular, nonvascular, and overall mortality. (A) Total effects: Cox pro-
portional hazards models stratified by country and adjusted for age, sex, black ethnicity, and study treatment assignment. Tests for
trend: c2 5 14.23; P , 0.001 for vascular deaths; c2 5 29.42; P, 0.001 for nonvascular deaths; c2 5 51.52; P, 0.001 for all deaths.
(B) Residual effects: Cox proportional hazards models stratified by country and adjusted for age, sex, black ethnicity, study treatment
assignment, smoking, alcohol use, body mass index, chronic kidney disease stage, prior vascular disease, diabetes, renal diagnosis,
systolic and diastolic blood pressure, albumin level, urinary albumin-creatinine ratio, hemoglobin level, phosphate level, high-density
lipoprotein cholesterol level, and total cholesterol level. The size of a square representing a relative risk is proportional to its inverse
variance; error bars represent 95% confidence intervals (CIs). Tests for trend in all models were evaluated after excluding participants
with unrecorded education. Tests for trend: c2 5 2.76; P 5 0.1 for vascular deaths; c2 5 9.18; P 5 0.003 for nonvascular deaths;
c2 5 15.09; P , 0.001 for all deaths.
Morton et alImportant behavioral differences were observed ac-
ross education groups. People with higher educational
attainment were much less likely to be current smokers
and, among those who are or have been smokers, were
more likely to have quit smoking than those of lower
educational attainment. Lower education level was
associated with obesity, although this association was
much weaker than for smoking. These associations are
likely to affect both vascular and nonvascular mortality
directly.20 However, alcohol consumption was more
common among those with higher educational attain-
ment. Although alcohol consumptionmight be a marker
of “better health” (ie, consumption may decrease
with deteriorating health),21 our data are limited in their36ability to test this hypothesis. Contrary to other studies,22
we did not ﬁnd a signiﬁcant difference across education
levels in adherence to study medication or a signiﬁcant
difference by educational attainment in proportions who
withdrew from the study (including for reasons of non-
adherence) between initial screening and ﬁnal random-
ization (trend c25 2.30; P5 0.1). In our analyses, the
inclusion of all available likely effect mediators explains
most of the effects of educational attainment on adverse
health outcomes in CKD; however, separating the
contribution of these potential mediators is not possible
due to the complex relationships between them.
It was unknown a priori whether educational
attainment would be associated with CKDprogression.Am J Kidney Dis. 2016;67(1):31-39
Figure 3. Relevance of highest education level attained
among 6,245 participants not on dialysis therapy at randomiza-
tion to progression to end-stage renal disease or doubling of
creatinine level. Participants with end point, n5 2,446. Test for
trend, Wald c2 5 0.71; P5 0.4. Cox proportional hazards model
stratified by country and adjusted for age, sex, black ethnicity,
and study treatment assignment. The size of the square repre-
senting a relative risk is proportional to its inverse variance; error
bars represent 95% confidence intervals (CIs). Tests for trend in
all models were evaluated after excluding participants with unre-
corded education.
Impact of Education on Outcomes in CKDA greater rate of progression to ESRD in patients with
high educational attainment has previously been re-
ported,23 although the potential for selection bias in this
small study that excluded patients at high risk of CKD
progression was substantial. A second study of patients
with CKD stages 3 to 4 reported no signiﬁcant effect of
educational attainment on progression to ESRD.24
However, the lack of an education gradient in CKD
progression in our study was consistent across a num-
ber of outcomes and unlikely due to a competing
mortality risk (ie, participants with lower educational
attainment are more likely to die before progressing).
First, there was no education gradient in progression to
ESRD or doubling of creatinine level (Figs 3 and S4).
Second, rates of decline in eGFR (a continuous marker
of CKD progression with increased statistical power)
were similar by stage of CKD, irrespective of educa-
tional attainment (Fig S5). Finally, there was also no
evidence for trend in progression to ESRD or death
from kidney failure speciﬁcally across education levels
in a Cox proportional hazards analysis adjusting for
age, sex, ethnicity, and study treatment assignment and
stratiﬁed by country (c2 5 1.72; P 5 0.2). The
marginally signiﬁcant interaction in education gradient
in CKD progression by study treatment assignment
(P 5 0.02) was in the absence of any overall effect of
allocation to simvastatin plus ezetimibe on CKD pro-
gression in the study.14
Highest educational attainment was selected as the
primary measure of socioeconomic status because it isAm J Kidney Dis. 2016;67(1):31-39less likely than other measures, such as income or
employment, to have been inﬂuenced by disease at
study entry (because it is usually completed in early life,
before such disease emerges).25 Our analyses
are therefore unlikely to be susceptible to reverse cau-
sality bias. Furthermore, highest educational attainment
is considered the optimal indicator of socioeconomic
statuswhen themechanismof effect on health outcomes
is thought to be through knowledge and health behav-
iors and when an older population is studied.25 House-
hold income data within 4 country-speciﬁc categories
were collected; however, these data were not used in the
main analyses because 33% of participants did not
provide reliable income data at baseline, and income is
likely to mediate the effects of educational attainment.
However, in sensitivity analyses, the inclusion of
household income in the residual effects models did not
affect results for any of the outcomes. In a further
sensitivity analysis, the tertiary and completed high
school levels of educational attainment were combined
to control for the possibility that access to tertiary edu-
cation might be income dependent; trends across
educational categories remained similar. P values for
trend across these 5 education levels, after adjustment
for age, sex, black ethnicity, and study treatment
assignment and stratifying by country, were P , 0.001
(c25 13.93) for vascular events, P 5 0.001
(c25 10.90) for vascular mortality, and P , 0.001
(c25 26.79) for nonvascular mortality, suggesting that
the gradients we report are unlikely to be unduly inﬂu-
enced by teriary-educated individuals.
Strengths of this study include its large size and
inclusion of a wide range of patients with moderate to
severe CKD and well-documented adverse health
outcomes during the nearly 5-year median period of
follow-up. Use of well-deﬁned categories of educa-
tional attainment enabled assessment of a graded
relationship across the 6 education levels, which was
more powerful than the dichotomous exposure vari-
ables used in other studies.23,24,26 We used valid
statistical methods to determine RRs of all outcomes
and provided a clear rationale for adjustment of po-
tential confounders, while avoiding overadjustment
for potential effect mediators.
Limitations of the study include potential selection
bias due to study inclusion criteria (ie, excluding people
with prior major coronary disease, severe respiratory
disease, or recent cancer may have prevented less
educated and potentially sicker patients from partici-
pating). However, the likely impact of such bias would
be that the effect of low educational attainment on
mortality outcomes might be underestimated. In addi-
tion, an inverse association between risk factors and
educational attainment may have been created through
the deliberate selection of participants with CKD into
SHARP that would not be present in an unselected37
Morton et alpopulation. This is a special case of “collider bias”27
that occurs when an outcome (eg, vascular death)
shares common risk factors with developing CKD; this
can result in the associations being biased toward the
null. Such selection bias may explain at least in part the
lack of association between education level and CKD
progression in SHARP. While we attempted in our
analyses to control for potential confounders and also to
estimate associations before and after adjustment for
potential effect mediators, it remains possible that
biases due to residual confounding or due to unmea-
sured factors associated with both the effect mediators
and outcome could still exist. Finally, further socio-
economic indicators such as participant income,
employment level, or health insurance status, if avail-
able, may allow investigation of the extent to which
these indicators modify the education-morbidity
gradient. Further research into the causal mechanisms
for the observed education-mortality gradient in people
with moderate to severe CKD is needed.
The strong association between educational attain-
ment and morbidity and mortality in moderate to se-
vere CKD is consistent with ﬁndings in other chronic
diseases (ie, heart failure, diabetes, and chronic lung
disease).28-31 We have shown that known risk factors,
more prevalent in individuals with lower levels of
education, are likely to mediate most of these effects.
The implications of our study for clinical practice and
policy are that, although risk factors for disease risks
are similar irrespective of educational attainment,
approaches to prevention might need to be tailored to
be effective among people with lower levels of edu-
cation (eg, literature to help smokers quit written at
upper primary school level).32 Such targeted inter-
ventions also include improved communication from
health professionals about chronic disease self-
management and personal risk.33,34 A direct link be-
tween low educational attainment and health literacy
is known and recent research has highlighted different
perceptions of personal risk among people with low
compared to high health literacy.35
Low educational attainment is associated with
increased cardiovascular risk and mortality for people
with moderate to severe CKD. Modiﬁable lifestyle
factors (eg, cigarette smoking) and prior diseases
explained much of the observed association. Educa-
tional attainment was not associated with increased
risk of CKD progression.These ﬁndings suggest that
educational attainment should be taken into account
when implementing interventions to reduce risk of
adverse health outcomes in CKD.
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